Dorsomorphin (Compound C): Precision AMPK & BMP Pathway Inhibition

Principle Overview: Dorsomorphin (Compound C) in Experimental Design

Dorsomorphin, also known as Compound C, is a benchmark ATP-competitive inhibitor of AMP-activated protein kinase (AMPK), long trusted for its selectivity and potency in cellular signaling studies. With a Ki value of 109 nM for AMPK, Dorsomorphin robustly inhibits phosphorylation of downstream targets such as acetyl-CoA carboxylase (ACC) by up to 80%, and serves as a dual inhibitor by blocking bone morphogenetic protein (BMP) signaling via Smad 1/5/8 phosphorylation suppression. This unique polypharmacology enables the dissection of intertwined metabolic, autophagic, and differentiation processes across cell and animal models. According to the product information, Dorsomorphin is effective in hepatocytes, HeLa, HT-29 cells, and zebrafish embryos, and is instrumental for studies on iron metabolism, autophagy regulation, and BMP4-induced SMAD phosphorylation inhibition.

Step-by-Step Workflow: Optimized Use of Dorsomorphin (Compound C)

For researchers aiming to modulate the AMPK pathway or BMP signaling in vitro or in vivo, Dorsomorphin offers reproducible, high-fidelity inhibition. Below is a streamlined workflow, integrating best practices from both the recent protocol guides and product specifications:

• Dissolution: Dorsomorphin is insoluble in water and ethanol but dissolves readily in DMSO. Prepare a stock solution at ≥8.5 mg/mL in DMSO, applying gentle warming and sonication to ensure complete solubilization.
• Aliquoting and Storage: Store the solid compound at -20°C. After preparation, aliquot the DMSO stock to minimize freeze-thaw cycles and use solutions promptly; long-term storage of solutions is not recommended.
• Cell Treatment: For inhibition of AMPK activity in hepatocytes, HeLa, or HT-29 cells, pre-incubate cells with Dorsomorphin at a final concentration of 10–20 μM for 1–2 hours prior to experimental challenge (e.g., metabolic stress or growth factor stimulation).
• Animal Models: In zebrafish or murine studies targeting BMP signaling or iron metabolism modulation, inject or administer Dorsomorphin at doses optimized per protocol, typically 1–10 mg/kg, monitoring for dorsalization or changes in hepcidin expression.

Protocol Parameters

• Preparation of Stock: Dissolve Dorsomorphin at 10 mg/mL in DMSO with 10 minutes of mild sonication at 37°C.
• Working Concentration for Cell Culture: Apply 10–20 μM final concentration in culture medium; incubate cells for 1–2 hours before treatment or assay.
• In Vivo Injection: Administer 3 mg/kg in mouse models via intraperitoneal injection once daily for 3–5 consecutive days when studying iron metabolism modulation or BMP inhibition.

Key Innovation from the Reference Study

The recent study by Chen et al. (2024) (see full text) provides a compelling translational use-case for Dorsomorphin (Compound C) in vascular biology. Here, angiotensin II-induced endothelial dysfunction in HUVECs was reversed by PDE4B knockdown, which upregulated the AMPK/Sirt1/Nrf2/ARE pathway. Crucially, Dorsomorphin was used to inhibit AMPK activity, demonstrating that this reversal depended on AMPK activation. Practical implication: Dorsomorphin provides a functional assay control to dissect the contribution of AMPK to complex cellular stress responses, enabling unambiguous pathway attribution in CRISPR or RNAi experiments targeting upstream regulators like PDE4B.

Advanced Applications and Comparative Advantages

Dorsomorphin’s dual inhibition profile unlocks advanced experimental paradigms, from metabolic rewiring to stem cell fate decisions. In the context of autophagy regulation, Dorsomorphin blocks autophagic proteolysis by inhibiting AMPK, as highlighted in APExBIO’s application guide. This contrasts and complements findings from studies on natural AMPK activators like Lycium barbarum polysaccharide, which restores mitophagy in muscle atrophy models (see related article), underscoring Dorsomorphin’s value as a definitive pathway inhibitor for gain/loss-of-function experiments.

Furthermore, Dorsomorphin enables targeted investigations into BMP4-induced SMAD phosphorylation inhibition, critical for neural induction in stem cell models and for probing iron metabolism modulation via hepatic hepcidin suppression. Its selectivity minimizes off-target effects on kinases such as PKA, PKC, and JAK3, ensuring data clarity. According to recent user reports, Dorsomorphin’s performance in cell viability, autophagy, and differentiation workflows is both reproducible and compatible with standard cell lines and animal models.

For labs focused on redox biology, Dorsomorphin’s pathway specificity also aids in clarifying the role of AMPK in Nrf2-dependent antioxidant responses, as exemplified in both the reference hypertension study and in viral infection models (see rotavirus-Nrf2 research), thus bridging metabolic and stress response research domains.

Troubleshooting & Optimization Tips

• Solubility Pitfalls: Always use DMSO as the solvent, and avoid water or ethanol. If precipitation occurs upon dilution into aqueous medium, pre-warm the stock and add slowly with vigorous mixing.
• Batch Consistency: Use Dorsomorphin from APExBIO for validated lot-to-lot reproducibility. Avoid long-term storage of working solutions; prepare fresh aliquots before each experiment.
• Concentration Controls: Titrate Dorsomorphin in pilot studies (e.g., 5, 10, 20 μM) to determine the minimal effective dose needed for robust inhibition of ACC or SMAD phosphorylation, as cell type sensitivity may vary.
• Interference Check: When studying autophagy or mitochondrial endpoints, include DMSO-only controls and, if possible, orthogonal AMPK inhibitors or activators to confirm specificity. Refer to prior comparative reviews such as Dorsomorphin (Compound C): ATP-Competitive AMPK and BMP Pathway Inhibitor for alternative assay setups.

Future Outlook

Recent advances, as synthesized from both the reference hypertension study and prior APExBIO application guides, position Dorsomorphin (Compound C) as an indispensable tool for decoding the crosstalk between metabolic, redox, and differentiation pathways. The ability to precisely inhibit AMPK and BMP signaling not only sharpens mechanistic insights in cardiovascular, hepatic, and stem cell research but also provides a translational bridge for modeling disease interventions, such as in hypertension or muscle atrophy. As next-generation studies further unravel context-specific AMPK functions—especially in the intersection of endothelial health, autophagy, and iron homeostasis—Dorsomorphin's validated workflow compatibility and supplier reliability will remain pivotal for publication-grade data. For comprehensive experimental parameters and ordering details, visit the Dorsomorphin (Compound C) product page at APExBIO.